EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

What We Can Do in Infectious Keratitis, Except for Conventional Antimicrobial‐Based Therapies: Major Narrative Review

Kasra Cheraqpour iD

Health Science Reports · 2026-03 · 9 (3)

DOI: 10.1002/hsr2.72034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Science Reports, online erschienen am 16.03.2026. Verfasst von Kasra Cheraqpour. Beteiligte Einrichtung: Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences Tehran Iran. Die Arbeit nennt 199 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Infectious keratitis (IK) is classified as a critical ophthalmic emergency, with the potential to result in vision‐impairing complications. The treatment approach involves the use of pharmacological antimicrobial agents in combination with surgical interventions. Traditionally, the management of IK has relied on conventional antimicrobial agents, although the specific treatment regimen may vary based on the underlying causative agent. The growing antimicrobial resistance, along with the less favorable outcomes in most cases, emphasizes the urgent need for adjunctive or novel therapies. This report aims to provide a thorough overview of the current clinical and experimental non‐antimicrobial therapies, encompassing both medical and surgical options, whether they serve as adjuncts to antimicrobial treatments or function as independent therapies for IK.

Methods

A comprehensive search on PubMed was undertaken to identify relevant articles. Articles that described conventional antimicrobial‐based treatments were excluded from the review. Additionally, case reports and non‐English publications were not considered.

Results

Various therapeutic options, including medical‐based therapies (povidone‐iodine, matrix metalloproteinases inhibitors, corticosteroids, host defense peptides, novel small molecules, formaldehyde releasers, synthetic polymers, antioxidants, and bacteriophages), laser/light‐based therapies (photodynamic therapy, ultraviolet C light, thermal lasers, photothermal therapy, phototherapeutic keratectomy, and blue light), surgical‐based therapies (conjunctival flap and Tenon graft, corneal gluing, amniotic membrane transplantation, and keratoplasty), and miscellaneous therapies (nanomedicine and contact lens, plasma ablation, debridement, and cryotherapy) were included and discussed.

Conclusion

The conventional approach to managing IK involves the use of topical antimicrobial agents. Most instances can be effectively addressed with empirical treatment using antimicrobial eye drops, yielding satisfactory results. However, it seems the rise in antimicrobial resistance and insufficient response in some cases, especially fungal keratitis, necessitates ophthalmologists to utilize all currently available options in their toolbox more efficiently and intensify research efforts aimed at developing alternative therapeutic strategies.

Schlagwörter

Stichwörter der Autor:innen

antimicrobialcorneal ulcerkeratitismanagementtherapytreatment

Autor:innen und Institutionen

  • Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences Tehran Iran.

ORCID-Profile: Kasra Cheraqpour

Zitieren

APA

Cheraqpour, K. (2026). What We Can Do in Infectious Keratitis, Except for Conventional Antimicrobial‐Based Therapies: Major Narrative Review. Health Science Reports, 9(3). https://doi.org/10.1002/hsr2.72034

Vancouver

Cheraqpour K. What We Can Do in Infectious Keratitis, Except for Conventional Antimicrobial‐Based Therapies: Major Narrative Review. Health Science Reports. 2026;9(3). doi:10.1002/hsr2.72034

BibTeX
@article{Cheraqpour2026,
  author = {Cheraqpour, Kasra},
  title = {What We Can Do in Infectious Keratitis, Except for Conventional Antimicrobial‐Based Therapies: Major Narrative Review},
  journal = {Health Science Reports},
  year = {2026},
  volume = {9},
  number = {3},
  doi = {10.1002/hsr2.72034}
}
Kostenlos starten →